First Berlin Equity Research has published a correction of the coverage initiation on Cantourage Group SE (ISIN: DE000A3DSV01/ Bloomberg: HIGH GR) published on 07/05/2026. Analyst Ellis Acklin placed a BUY rating on the stock with a EUR 11.00 price target.

Abstract
We start coverage of Cantourage Group SE with a Buy rating and €11 TP (upside: 77%). The company offers differentiated exposure to the European medical cannabis market through a capital-light platform that unites sourcing, processing and distribution across regulated and telemedicine channels. In our view, Cantourage is also more regulator-resilient than the market appears to assume. German reform risk has cast a pall over the equity story, but we think the business is well equipped to adapt through its diversified product portfolio, pharmacy access and expanding geographic reach. As reform concerns fade, we see scope for investors to focus more squarely on the company’s growth prospects, improving profitability and embedded margin upside.